stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) EV/FCF
As of 5 November 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a EV/FCF of 22.9×. Over the past ten years it has ranged from −832× (March 2025) to 2,297× (October 2024); the current reading is higher than 82% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 109× | — |
| FY2024 | −666× | — |
| FY2023 | 547× | — |
| FY2022 | −44.4× | — |
| FY2021 | −25.5× | — |
| FY2020 | −19.4× | — |
| FY2019 | −27.1× | — |
| FY2018 | −9.1× | — |
| FY2017 | −21.1× | — |
| FY2016 | −7.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 37.8× | (18.36%) |
| Jun 2026 | 46.3× | (29.10%) |
| Mar 2026 | 65.2× | (40.09%) |
| Dec 2025 | 109× | (68.75%) |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | −39.7× |
| INSM Insmed, Inc. compare | −37.2× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| EXEL Exelixis, Inc. compare | 14.1× |
| ALNY Alnylam Pharmaceuticals, Inc. | 22.9× |
| JAZZ Jazz Pharmaceuticals PLC compare | 26.2× |
| INCY Incyte Corporation compare | 29.7× |
| ASND Ascendis Pharma A/S compare | 41.1× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement